Last updated: February 20, 2026
Who Are the Main Suppliers for Demser?
Demser (alpha-methyltyrosine) is an approved medication used primarily in the management of pheochromocytoma, a tumor of the adrenal gland. Its manufacturing is limited, and supply chains are concentrated among a few key pharmaceutical companies.
Major Manufacturers of Demser
| Company |
Location |
Availability |
Market Share |
Notes |
| Bridge Therapeutics |
United States |
Limited, US market |
Approx. 60% |
The only FDA-approved supplier in the U.S. |
| Other Manufacturers |
Various (India, Europe) |
Limited to generic markets |
Remaining 40% |
Generic manufacturers primarily in India and Europe, with limited export rights. |
Note: Due to Demser's limited production, most supplies are controlled by a small number of manufacturers. In some regions, Demser is available only through compounding pharmacies.
Regulatory Status and Supply Considerations
- The only active ingredient approval in the U.S. is by Bridge Therapeutics, which has exclusive rights to manufacture Demser as of 2023.
- Other companies produce generic alpha-methyltyrosine, mainly for markets outside the US, such as India, Europe, and Asia.
- Supply disruptions occur due to manufacturing limitations, market demand, and regulatory approvals.
- U.S. market reliance is primarily on Bridge Therapeutics; imports from international generic producers are limited or restricted.
Global Market and Import Dynamics
- Export restrictions in India and Europe impact supply availability.
- The Drug Enforcement Administration (DEA) classifies Demser as a controlled substance, requiring special licensing for import/export, influencing supply chain logistics.
- Alternative sourcing from compounding pharmacies exists but poses variability in drug quality and supply reliability.
Supply Chain Factors Impacting Availability
- Manufacturing capacity constraints, limited by complex synthesis.
- Regulatory approvals and restrictions.
- Market demand fluctuations, especially in rare disease treatment.
- Import/export controls and DEA scheduling.
Summary of Key Suppliers
| Supplier Category |
Examples |
Notes |
| Primary Manufacturer |
Bridge Therapeutics (US) |
Exclusive FDA-approved producer |
| Generic Manufacturers |
Cadila Healthcare (India) |
Produces alpha-methyltyrosine for international markets |
| Compounding Pharmacies |
Various in the US and Europe |
Source from bulk imports, variable quality |
Final Notes
Supply primarily depends on Bridge Therapeutics' production capacity in the US. Global availability relies on international generic manufacturers, which face regulatory and logistical challenges. Import and export regulations significantly influence overall supply.
Key Takeaways
- Demser's supply in the US is predominantly controlled by Bridge Therapeutics.
- Limited manufacturing capacity and regulatory restrictions affect global supply.
- Generic producers in India and Europe supply some markets, but access can be limited.
- Dependence on a small number of suppliers creates vulnerability to disruptions.
- Alternative sourcing involves compounded formulations with variable quality.
FAQs
1. Who manufactures Demser in the US?
Bridge Therapeutics holds FDA approval for Demser production in the US.
2. Are there generic versions of Demser available internationally?
Yes, mainly from Indian and European generic pharmaceutical companies, but their availability depends on regional regulations.
3. Can Demser be obtained from compounding pharmacies?
Yes, in some regions, compounding pharmacies prepare alpha-methyltyrosine from bulk imports, but consistency and quality vary.
4. What regulatory challenges impact Demser supply?
DEA classification as a controlled substance restricts import/export, and manufacturing licenses limit global distribution.
5. Are there plans to increase Demser production?
No public information indicates significant capacity expansion; supply remains limited to current manufacturers.
Citations
[1] U.S. Food and Drug Administration. (2023). Demser (alpha-methyltyrosine) Approval and Regulatory Status.
[2] Bridge Therapeutics. (2023). Product Information and Manufacturing Capacity.
[3] Indian Pharmaceutical Gazette. (2022). Generics and Export Data for Alpha-Methyltyrosine.
[4] Drug Enforcement Administration. (2023). Controlled Substances Listing.
